ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,770.20
0.55%
Dow Jones
42,801.72
0.52%
US Dollar vs MXN
20.26717
0.00%
Brent Oil
70.235
0.00%
Bitcoin
85,913.65
-0.28%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. BioCryst Pharmaceuticals Inc (BCRX) Cotización

BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX)

NASDAQ
7.69
-0.17
(-2.16%)
Cerrado 09 Marzo 2:00PM
Delayed by 15 minutes
7.70
0.01
(0.13%)
Fuera de horario: 6:56PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
7.70
Postura de Compra
7.60
Postura de Venta
7.77
Volume Operado de la Acción
4,078,144
7.585 Rango del Día 7.965
4.03 Rango de 52 semanas 9.50
Capitalización de Mercado [m]
1.609B
Precio Anterior
7.86
Precio de Apertura
7.86
Hora
55
@
7.6
Última hora de negociación
Volumen financiero
US$ 31,708,528
Precio Promedio Ponderado
7.7752
Volumen promedio (3 m)
2,940,891
Acciones en circulación
208,960,020
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-18.03
Beneficio por acción (BPA)
-0.43
turnover
450.71M
Beneficio neto
-88.88M

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, ... BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.biocryst.com
Sede
Wilmington, Delaware, USA
Fundado
-
BioCryst Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BCRX. The last closing price for BioCryst Pharmaceuticals was US$7.86. Over the last year, BioCryst Pharmaceuticals shares have traded in a share price range of US$ 4.03 to US$ 9.50.

BioCryst Pharmaceuticals currently has 208,960,020 shares in issue. The market capitalisation of BioCryst Pharmaceuticals is US$1.64 billion. BioCryst Pharmaceuticals has a price to earnings ratio (PE ratio) of -18.03.

BCRX Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Marzo 2025
BCRX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
04 Marzo 2025
BCRX (-2.16%)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
25 Febrero 2025
BCRX (-2.16%)

Form 8-K - Current report
Edgar (US Regulatory)
24 Febrero 2025
BCRX (-2.16%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.77-9.090909090918.478.87.6749393228.27494186CS
4-1.05-128.759.57.6741598588.67847931CS
120.162.122015915127.549.56.9629408918.20903831CS
26-0.3-3.7589.56.84523674927.94359311CS
522.4546.66666666675.259.54.0327887086.85070439CS
156-8.266-51.772516597815.96618.64.0330713388.59481125CS
2603.4279.90654205614.2819.991.5840852838.35240025CS

BCRX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de BioCryst Pharmaceuticals?
El precio actual de las acciones de BioCryst Pharmaceuticals es US$ 7.70
¿Cuántas acciones de BioCryst Pharmaceuticals están en circulación?
BioCryst Pharmaceuticals tiene 208,960,020 acciones en circulación
¿Cuál es la capitalización de mercado de BioCryst Pharmaceuticals?
La capitalización de mercado de BioCryst Pharmaceuticals es USD 1.64B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals ha negociado en un rango de US$ 4.03 a US$ 9.50 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de BioCryst Pharmaceuticals?
El ratio precio/beneficio de BioCryst Pharmaceuticals es -18.03
¿Cuál es el ratio de efectivo a ventas de BioCryst Pharmaceuticals?
El ratio de efectivo a ventas de BioCryst Pharmaceuticals es 3.56
¿Cuál es la moneda de reporte de BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de BioCryst Pharmaceuticals?
El último ingresos anual de BioCryst Pharmaceuticals es USD 450.71M
¿Cuál es el último beneficio anual de BioCryst Pharmaceuticals?
El último beneficio anual de BioCryst Pharmaceuticals es USD -88.88M
¿Cuál es la dirección registrada de BioCryst Pharmaceuticals?
La dirección registrada de BioCryst Pharmaceuticals es 2711 CENTERVILLE ROAD, NEW CASTLE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de BioCryst Pharmaceuticals?
La dirección del sitio web de BioCryst Pharmaceuticals es www.biocryst.com
¿En qué sector industrial opera BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CAPSCapstone Holding Corp
US$ 3.50
(1,300.00%)
36.33k
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.13M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
476.73M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
618.03M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.77M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

BCRX Discussion

Ver más
rosemountbomber rosemountbomber 2 semanas hace
What is this company doing?  No wonder Denner bailed.  
👍️0
Monksdream Monksdream 2 semanas hace
BCRX 10Q due MONDAY 2/24
👍️0
rosemountbomber rosemountbomber 2 meses hace
What is going on here, stock price whipsawed from one day to the next. Doesn't seem like any rhyme or reason.
👍️0
Monksdream Monksdream 3 meses hace
BCRX, under $8
👍️0
Monksdream Monksdream 4 meses hace
BCRX under $10

👍️0
Monksdream Monksdream 7 meses hace
BCRX under $8
👍️0
Monksdream Monksdream 10 meses hace
BCRX new 52 week low
👍️0
Monksdream Monksdream 10 meses hace
BCRX new 52 lo
👍️0
Monksdream Monksdream 11 meses hace
BCRX new 52 week lo
👍️0
Monksdream Monksdream 11 meses hace
BCRX under $10
👍️0
Monksdream Monksdream 1 año hace
BCRX 10Q 2/26
👍️0
Calcumad Calcumad 1 año hace
It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
👍️0
james kent james kent 2 años hace
when will it turn around?
👍️0
james kent james kent 2 años hace
when will it turn around?
👍️0
ttubular ttubular 2 años hace
Huge buys in AH
👍️0
VivaLasVegas VivaLasVegas 2 años hace
Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?
👍️0
ttubular ttubular 3 años hace
6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
👍️0
rosemountbomber rosemountbomber 3 años hace
Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
👍️0
conix conix 3 años hace
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
👍️0
Cosa Cosa 3 años hace
I guess it was perfect timing in a way...
👍️0
Cosa Cosa 3 años hace
I reduced my position here to buy more AUPH (facepalm)
👍️0
starkd748 starkd748 3 años hace
13.90s pullback yesss
👍️0
starkd748 starkd748 3 años hace
Overbought pullback in progress TA saves money
👍️0
Limey42 Limey42 3 años hace
You were saying? LMFAO!!!!!!!!
👍️0
game7alcs game7alcs 3 años hace
BCRX just on CNBC for large call volume action
👍️0
starkd748 starkd748 3 años hace
Burnt to a crisp rsi enjoy
👍️0
starkd748 starkd748 3 años hace
Lmfao the rsi is 100 pullback in progress
👍️0
ttubular ttubular 3 años hace
Understatement
👍️0
Limey42 Limey42 3 años hace
This company is a juggernaut!
👍️0
plexrec plexrec 3 años hace
Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
👍️0
ezyE ezyE 3 años hace
Great buying opportunity.
Shouldn't be this low.
👍️0
easyrider1 easyrider1 3 años hace
What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
👍️0
easyrider1 easyrider1 3 años hace
Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
👍️0
starkd748 starkd748 3 años hace
Might buy some options here
👍️0
easyrider1 easyrider1 3 años hace
Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
👍️0
MZlu MZlu 3 años hace
I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.
👍️0
easyrider1 easyrider1 3 años hace
First sign of life….someone realizes that this a buy
👍️0
Deano361 Deano361 3 años hace
Yeah been 18 months now and holding for me . I thin pnh results soon will help us
👍️0
easyrider1 easyrider1 3 años hace
I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
👍️0
Deano361 Deano361 3 años hace
Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
👍️0
Cosa Cosa 3 años hace
The sharp increase in revenue is what got my attention!
👍️0
Cosa Cosa 3 años hace
"Facepalm" I jinxed you guys.
👍️0
bhulkupk bhulkupk 3 años hace
Hi Cosa, welcome…
👍️0
Deano361 Deano361 3 años hace
Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
👍️0
Cosa Cosa 3 años hace
Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
👍️0
easyrider1 easyrider1 4 años hace
Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
👍️0
Deano361 Deano361 4 años hace
Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
👍️0
bhulkupk bhulkupk 4 años hace
Oh okay, so I can buy some for long term? Thanks in advance.
👍️0
Deano361 Deano361 4 años hace
It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
👍️0
bhulkupk bhulkupk 4 años hace
How?
👍️0

Su Consulta Reciente

NASDAQ
BCRX
BioCryst Pharmaceuticals
BIT
S24910
SG ISSUER
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios